Tech Company Financing Transactions
Octant Funding Round
On 4/21/2022, Octant raised $80 million in Series B funding from Catalio Capital Management.
Transaction Overview
Company Name
Announced On
4/21/2022
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series B
Investors
Catalio Capital Management (Lead Investor)
Proceeds Purpose
This investment will help propel Octant forward in all facets of our business and accelerate our ability to develop life-changing drugs and therapies for some of the world's most challenging diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1464 67th St.
Emeryville, CA 94608
USA
Emeryville, CA 94608
USA
Phone
Undisclosed
Website
Email Address
Overview
Octant is advancing a new paradigm of drug discovery. Our polypharmacology discovery engine generates multi-receptor pathway data and predictive insights to inform rational drug design with unprecedented speed, scale and precision. We engineer biology using living cells as high-throughput signal networks to map, measure and model chemical structures against G protein-coupled receptors (GPCRs).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sri Kosuri
President
Ramsey Homsany
Browse more venture capital transactions:
Prev: 4/21/2022: Ordinary Folk venture capital transaction
Next: 4/21/2022: Crusoe Energy Systems venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs